India Gleevec shangmao purchasing agent 13621079267 India 120 capsules Gleevec

Editing of Usage and Dosage
Starting dose: For patients in the blast phase and accelerated phase of chronic myelogenous leukemia, the recommended dose of imatinib mesylate is/day. For patients in the chronic phase who have failed interferon therapy, as well as those who cannot be surgically resected or For patients with metastatic malignant gastrointestinal stromal tumors (), the recommended dose is/day, which should be taken orally once a day. It is advisable to take the medicine with meals and drink a large glass of water. As long as it is effective, it should be continued.
If the blood picture permits and there are no serious adverse drug reactions, the dose may be considered to be increased from / day to / day, or from / day to / day (taken in divided doses) under the following circumstances: disease progression, treatment of at least several After 1 month, satisfactory hematological response could not be obtained, and the hematological response that had been achieved disappeared again.
The dose must be adjusted in the following circumstances: If serious non-hematological adverse reactions (such as severe water retention) occur during treatment, the drug should be discontinued until the adverse reactions disappear, and then the dose will be adjusted according to the severity of the adverse reactions.
Adjustment of dosage in case of severe liver toxicity: If the increase in bilirubin exceeds the upper limit of the normal range or the increase in transaminase exceeds the upper limit of the normal range, the drug should be discontinued until the above indicators drop to the upper limit of the normal range respectively. Or . times or less.
Dose adjustment in neutropenia or thrombocytopenia: Acceleration or blast phase: If severe neutropenia and thrombocytopenia occur (neutrophils less than.&/or platelets less than&/recommended dose Reduce to / day. If blood cells continue to decrease for weeks, further reduce the dose to / day. If blood cells continue to decrease for weeks, it is advisable to discontinue the drug until neutrophils &.
&-Patients in the chronic phase after interferon treatment failure: it is advisable to discontinue the drug when the neutrophils are less than . To resume medication, the dose is /day. If neutrophils or platelets are reduced to the above values again, the dose is reduced to /day when medication is resumed.
Dosage for patients with liver failure: Methanesulfonate for patients with liver function impairment The plasma concentration of imatinib mesylate can increase, so these patients should be cautious when using this drug. There are no clinical data on the use of imatinib mesylate in patients with liver function impairment, and no recommendations for dosage adjustment can be made.
Dosage in Renal Failure and Elderly Patients: Creatinine clearance is known to decrease with age, while age has no significant effect on the pharmacokinetics of imatinib mesylate, as it has not been studied in patients with renal impairment. No clinical trials have been conducted, so no recommendations for dosage adjustment can be made